- Home
- ATYR
as 05-09-2025 3:31pm EST
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 290.6M | IPO Year: | 2015 |
| Target Price: | $18.60 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.42 - $4.66 | Next Earning Date: | 05-07-2025 |
| Revenue: | N/A | Revenue Growth: | -33.43% |
| Revenue Growth (this year): | 551.06% | Revenue Growth (next year): | 2144.84% |
Latest aTyr Pharma Inc. Common Stock News
ATYR Breaking Stock News: Dive into ATYR Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
Simply Wall St.
10 days ago
When Will aTyr Pharma, Inc. (NASDAQ:ATYR) Turn A Profit?
GlobeNewswire
11 days ago
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Simply Wall St.
a month ago
US High Growth Tech Stocks to Watch in 2023
GlobeNewswire
a month ago
aTyr Pharma to Participate in April Investor Conferences
GlobeNewswire
a month ago
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
GuruFocus.com
2 months ago
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...
Compare ATYR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATYR aTyr Pharma Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.